CXCL10 and COVID-19: In regards to our study, as the findings indicate that the association of the co-expressed genes that take part in different immune response mechanisms are common to both PRAD and COVID-19, it can be predicted that PRAD patients, as they have higher levels of CXCL10 (Fig. 2A), if diagnosed with COVID-19 have a possibility of developing cytokine storm mediated fatality.